31 May 2016 - The US FDA has approved Jentadueto XR (linagliptin and metformin hydrochloride extended release tablets) for the treatment of type 2 diabetes in adults.

Jentadueto XR, which is marketed by Boehringer Ingelheim and Eli Lilly and Company, is the seventh new treatment from the Boehringer Ingelheim-Lilly diabetes alliance to be approved by the FDA in the last five years.

Jentadueto XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both linagliptin and metformin is appropriate. Jentadueto XR should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, and has not been studied in people with a history of pancreatitis.

The Jentadueto XR label contains a boxed warning for the risk of lactic acidosis, a serious metabolic complication that can occur due to metformin accumulation during treatment with Jentadueto XR.

For more details, go to: http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2016/5-31-2016-us-fda-approves-once-daily-jentadueto-xr-linagliptin-metformin-hydrochloride-extended-release-tablets-adults-type-2-diabetes.html